Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

CONMED reports after the market close, meaning Day 0 reflects pre-announcement positioning while Day +1 captures the market's first full reaction to results.

CONMED's post-earnings price behavior shows moderate Day 0 moves averaging 2.05% as investors position ahead of results, followed by significantly larger Day +1 reactions averaging 5.85% once the market digests the actual numbers. The Day +1 range of 8.79% indicates substantial intraday volatility as traders reassess positions.

The most recent earnings cycle (July 2026) exemplified this pattern: the stock declined 2.35% on Day 0 but then surged 8.72% on Day +1 following the 25.45% earnings beat. This represented one of the stronger positive reactions in recent history. However, the data also reveals significant downside risk—the January 2026 report saw a 3.57% Day +1 decline despite a modest Day 0 drop, while February 2025 produced an 8.97% Day +1 plunge after an initial 1.54% gain.

The historical pattern suggests investors should prepare for a mid-to-high single-digit percentage move in the session following results, with direction heavily dependent on whether CONMED beats or misses estimates. Given the company's recent beat streak, a continuation of that trend could drive another strong positive reaction, while any disappointment relative to the lowered $1.00 estimate could trigger an outsized selloff given the stock's proximity to 52-week highs.

Part 2.2: Options Market Expected Move

The options market is not pricing in a significant expected move for this earnings event, with an implied move of 0.00%. This stands in stark contrast to CONMED's historical average Day +1 move of 5.85% and average Day +1 range of 8.79%, suggesting options traders may be underestimating potential volatility or the data may be incomplete. Investors should be prepared for price action more consistent with the historical pattern than what limited options positioning implies.

Part 3: What Analysts Are Saying

Analyst sentiment on CONMED remains decidedly cautious despite the stock's recent strength. The consensus rating stands at 2.88 out of 5.0—firmly in "Reduce" territory—with seven Hold ratings and one Sell rating among the eight analysts covering the stock. Notably, there are zero Buy recommendations, an unusual configuration for a company that has beaten earnings estimates four quarters in a row.

The average price target of $45.86 implies 2.8% downside from the current price of $47.20, with estimates ranging from a low of $43.00 to a high of $49.00. This narrow range suggests analysts are largely aligned in their view that the stock is fairly valued to slightly overvalued at current levels. The sentiment trend is classified as unchanged over the past month, indicating no recent catalyst has shifted the Street's perspective.

The disconnect between analyst caution and market performance is striking. While the stock has climbed above most of its key moving averages and trades near 52-week highs, the analyst community has maintained its defensive posture. Recent actions reinforce this stance: BMO Capital Markets initiated with a "market perform" rating and $36 target (well below current levels), while Needham reiterated its hold rating. Weiss Ratings upgraded CONMED from "sell" to "hold" in October, but this merely moved the stock from negative to neutral in their view.

The bearish tilt appears driven by valuation concerns—the stock trades at a forward P/E of 9.5 based on fiscal 2026 estimates, but analysts may be skeptical about growth prospects given the negative estimate revisions for upcoming quarters. The consensus implies that even if CONMED delivers another earnings beat, the stock's current price already reflects that potential upside. Investors should watch whether management's guidance on the October 28 call provides any catalyst for analysts to revisit their cautious stance.

Part 4: Technical Picture

CONMED enters earnings with a 72% Buy signal from the Barchart Technical Opinion, unchanged from last week but significantly stronger than the 40% reading from a month ago. This improvement reflects the stock's steady climb above key longer-term moving averages, though recent short-term momentum has begun to waver.

The current price of $47.20 sits below the 5-day ($48.14), 10-day ($47.31), and 50-day ($47.40) moving averages, indicating some near-term consolidation after the stock's recent run. However, CONMED remains above the 20-day ($46.40), 100-day ($43.99), and 200-day ($41.36) moving averages, confirming the broader uptrend remains intact. The stock is up over 14% from its 200-day average, demonstrating strong intermediate-term momentum.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal reflects recent consolidation and the pullback below the 5-day and 10-day averages, suggesting near-term momentum has cooled
• Medium-term (50% Buy): Neutral-to-positive reading indicates the stock is holding support at the 20-day average while digesting recent gains
• Long-term (100% Buy): Strong buy signal confirms the dominant uptrend remains firmly in place, with the stock well above all major long-term moving averages

Trend Characteristics: The technical setup shows Good strength but a Weakening direction, indicating that while the underlying trend remains positive, momentum is decelerating as the stock consolidates near resistance.

Key technical levels to watch include the 50-day moving average at $47.40, which has served as resistance in recent sessions, and the 20-day average at $46.40, which represents immediate support. The stock's position just below the 50-day suggests it's testing a critical inflection point heading into earnings. A beat-and-raise scenario could propel CONMED through the $48–$49 resistance zone toward the 52-week high of $53.66, while any disappointment could send the stock back toward the 20-day or even 100-day support levels. The weakening momentum and recent consolidation suggest the technical setup is neutral-to-cautious, with the earnings report likely to determine whether the stock breaks out to new highs or corrects back toward the rising 100-day average at $43.99.